ReviewPharmaceuticals (Basel, Switzerland)2022
Anticancer Activities of Mushrooms: A Neglected Source for Drug Discovery.
Review in Pharmaceuticals (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed.
- Artificial Intelligence-Assisted Optimization ofFoods (Basel, Switzerland) · 2026Article
- Biological activity of Pleurotus eryngii based on antioxidant, anticholinesterase and antiproliferative effects using optimized extraction methods.Scientific reports · 2026Article
- In vitro antiproliferative activity on A549 and HT-29 cell lines and fatty acid profiling of Agaricus bresadolanus and A. hortensis.Die Naturwissenschaften · 2026Article
- Evaluation of phenolic profile and multi-biological activities of Lepista glaucocana extracts optimized by ANN-GA and RSM models.Scientific reports · 2026Article
- The Inclusion of Dietary and Medicinal Mushrooms into Translational Oncology: Pros and Cons at the Molecular Level.International journal of molecular sciences · 2026Review
- Antioxidant and anticancer potentiality of F13 fraction of Pleurotus sajar caju against cancer cell lines and in silico analysis.Scientific reports · 2025Article
- Programmed cell death in triple-negative breast cancer.Cellular & molecular biology letters · 2025Review
- Exploring the Anticancer Potential ofCurrent issues in molecular biology · 2025Review
- From Mushrooms to Molecules: Exploring Depsidones inMolecules (Basel, Switzerland) · 2025Article
- Comparative study on the therapeutic potential of aqueous extracts from commercially cultivated Agaricus bisporus and Lentinula edodes in Sri Lanka: antioxidant, anticancer, antidiabetic, and antibacterial properties.BMC complementary medicine and therapies · 2025Article
- Harnessing the Nutritional Value, Therapeutic Applications, and Environmental Impact of Mushrooms.Food science & nutrition · 2025Review
- Identification and therapeutic efficacy of Pleurotus djamor var fuscopruinosus.Scientific reports · 2025Article
- Synthesis of fungal polysaccharide-based nanoemulsions for cancer treatment.RSC advances · 2025Article
- Mushroom marvels: understanding their role in human health.Frontiers in nutrition · 2025Review
- Review
- AnArhiv za higijenu rada i toksikologiju · 2024Article
- Edible mushrooms trending in food: Nutrigenomics, bibliometric, from bench to valuable applications.Heliyon · 2024Review
- Chemical Content and Cytotoxic Activity on Various Cancer Cell Lines of Chaga (Pharmaceuticals (Basel, Switzerland) · 2024Article
- Medicinal Mushrooms in Metastatic Breast Cancer: What Is Their Therapeutic Potential as Adjuvant in Clinical Settings?Current issues in molecular biology · 2024Review
- Strobilurin X acts as an anticancer drug by inhibiting protein synthesis and suppressing mitochondrial respiratory chain activity.Discover oncology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Approximately 270 species of mushrooms have been reported as potentially useful for human health. However, few mushrooms have been studied for bioactive compounds that can be helpful in treating various diseases. Like other natural regimens, the mushroom treatment appears safe, as could be expected from their long culinary and medicinal use. This review aims to provide a critical discussion on clinical trial evidence for mushrooms to treat patients with diverse types of cancer. In addition, the review also highlights the identified bioactive compounds and corresponding mechanisms of action among the explored mushrooms. Furthermore, it also discusses mushrooms with anticancer properties, demonstrated either in vitro and/or in vivo models, which have never been tested in clinical studies. Several mushrooms have been tested in phase I or II clinical trials, mostly for treating breast cancer (18.6%), followed by colorectal (14%) and prostate cancer (11.6%). The majority of clinical studies were carried out with just 3 species:
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.